Clinical Trial

The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
EFFEKTOR is a vanguard, multicenter, phase 2 randomized, double blinded, placebo controlled clinical trial to determine the feasibility, tolerability, safety, and efficacy of finerenone in kidney transplant recipients (KTRs). One hundred fifty (150) KTRs will be randomized in a 2:1 ratio of finerenone to placebo, with two embedded substudies: (i) a kidney biopsy substudy in 50 participants who undergo a research kidney biopsy prior to randomization and at the end of active treatment; and (ii) a functional MRI (fMRI) substudy in 50 participants who undergo fMRI prior to randomization and at the end of active treatment.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-09-25; most recent amendment 2026-04-09.
Status change: Not Yet Recruiting → Recruiting 2024-04-17
Trial Details
NCT Number NCT06059664
Lead Sponsor University of North Carolina, Chapel Hill
Collaborators: Bayer, Weill Medical College of Cornell University, University of Cincinnati
Conditions Kidney Transplant; Complications
Enrollment 100 participants
Start Date 2024-04-23
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-14